Page 34 - Haematologica - Vol. 105 n. 6 - June 2020

E.R.M. Scheepers et al.
6. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced- intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878-1867.
7. Hamaker ME, Stauder R, van Munster BC. Exclusion of older patients from ongoing clinical trials for hematological malignan- cies: an evaluation of the National Institutes of Health clinical trial registry. Oncologist. 2014;19(10):1069-1075.
8. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241-225.
9. Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT, Schols JM. Toward a conceptual defini- tion of frail community dwelling older peo- ple. Nurs Outlook. 2010;58(2):76-86.
10. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):146- 156.
11. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;8(1): 323-336.
12. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489- 495.
13. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326- 2347.
14. Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595-2601.
15. van Walree IC, Scheepers E, van Huis-Tanja LH, et al. A systematic review on the associ- ation of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. J Geriatr Oncol. 2019;10(6):847-858.
16. Goede V, Stauder R. Multidisciplinary care in the hematology clinic: implementation of geriatric oncology. J Geriatr Oncol. 2019;10(3):497-503.
17. Hamaker ME, Prins MC, Stauder R. The rel- evance of a geriatric assessment for elderly patients with a haematological malignancy - a systematic review. Leuk Res. 2014;(38): 275-283.
18. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assess- ing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, 2012.
19. Aguiar APN, Mendonça P da S, Ribeiro- Júnior HL, et al. Myelodysplastic syn- dromes: an analysis of non-hematological prognostic factors and its relationship to age. J Geriatr Oncol. 2020;(11):125-127.
20. Corsetti MT, Salvi F, Perticone S, et al. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res. 2011;35(8):991-997.
21. Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute
myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208- 216.
22. Holmes H, Des Bordes JKA, Kebriaei P, et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell trans- plantation candidates. J Geriatr Oncol. 2014;5(4):422-430.
23. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemother- apy for acute myelogenous leukemia. Blood. 2013;121(21):4287-4294.
24. Klepin HD, Ritchie E, Major-Elechi B, et al. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020;(11):107- 113.
25. Molga A, Wall M, Chhetri R, et al. Comprehensive geriatric assessment pre- dicts azacitidine treatment duration and sur- vival in older patients with myelodysplastic syndromes. J Geriatr Oncol. 2020;(11):114- 120.
26. Molga A, Wall M, Wee LYA, et al. Screening for deficits using the G8 and VES-13 in older patients with myelodysplastic syndromes. J Geriatr Oncol. 2020;(11):128-130.
27. Umit EG, Baysal M, Demir AM. Frailty in patients with acute myeloid leukaemia, con- ceptual misapprehension of chronological age. Eur J Cancer Care (Engl). 2018;27(2): e12810.
28. Goede V, Bahlo J, Chataline V, et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57(4):789-796.
29. Molica S, Giannarelli D, Levato L, et al. A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients. Leuk Lymphoma. 2019;60(3):845-847.
30. Ribi K, Rondeau S, Hitz F, et al. Cancer-spe- cific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma. Support Care Cancer. 2017;25(9):2833-2842.
31. Merli F, Cavallo F, Salvi F, et al. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. J Geriatr Oncol. 2020;(11):37-40.
32. Ong DM, Ashby M, Grigg A, et al. Comprehensive geriatric assessment is use- ful in an elderly Australian population with diffuse large B-cell lymphoma receiving rit- uximab-chemotherapy combinations. Br J Haematol. 2019;(187):73-81.
33. Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assess- ment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17(6):838-846.
34. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geri- atric assessment is more effective than clini- cal judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115(19): 4547-4553.
35. Tucci A, Martelli M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evalu- ation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma.
2015;56(4):921-926.
36. Aaldriks A, Giltay E, Nortier J, et al.
Prognostic significance of geriatric assess- ment in combination with laboratory parameters in elderly patients with aggres- sive non-Hodgkin lymphoma. Leuk Lymphoma. 2015;56(4):927-935.
37. Naito Y, Sasaki H, Takamatsu Y, Kiyomi F, Tamura K. Retrospective analysis of treat- ment outcomes and geriatric assessment in elderly malignant lymphoma patients. J Clin Exp Hematop. 2016;56(1):43-49.
38. Park S, Hong J, Hwang I, et al. Comprehensive geriatric assessment in eld- erly patients with newly diagnosed aggres- sive non-Hodgkin lymphoma treated with multi-agent chemotherapy. J Geriatr Oncol. 2015;6(6):470-478.
39. Siegel AB, Lachs M, Coleman M, Leonard JP. Lymphoma in elderly patients: novel func- tional assessment techniques provide better discrimination among patients than tradi- tional performance status measures. Clin Lymphoma Myeloma. 2006;7(1):65-69.
40. Soubeyran P, Khaled H, MacKenzie M, et al. Diffuse large B-cell and peripheral T-cell non-Hodgkin’s lymphoma in the frail elder- ly. A phase II EORTC trial with a progres- sive and cautious treatment emphasizing geriatric assessment. J Geriatr Oncol. 2011;2(1):36-44.
41. Winkelmann N, Petersen I, Kiehntopf M, Fricke HJ, Hochhaus A, Wedding U. Results of comprehensive geriatric assessment effect survival in patients with malignant lym- phoma. J Cancer Res Clin Oncol. 2011;137(4):733-738.
42. Okuyama T, Sugano K, Iida S, Ishida T, Kusumoto S, Akechi T. Screening perform- ance for frailty among older patients with cancer: a cross-sectional observational study of two approaches. J Natl Compr Cancer Netw. 2015;13(12):1525-1531.
43. Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: Validation of the International Myeloma Working Group (IMWG) score and comparison with ther common comor- bidity scores. Haematologica. 2016;101(9): 1110-1119.
44. Gavriatopoulou M, Fotiou D, Koloventzou U, et al. Vulnerability variables among octo- generian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019;60(3):619-628.
45. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074.
46. Rosko AE, Huang Y, Benson DM, et al. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol. 2019;10(3):479-85.
47. Wildes TM, Tuchman SA, Klepin HD, et al. Geriatric assessment in older adults with multiple myeloma. J Am Geriatr Soc. 2019;67(5):987-991.
48. Zhong YP, Zhang YZ, Liao AJ, Li SX, Tian C, Lu J. Geriatric assessment to predict survival and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients: A multicenter study in China. Chin Med J (Engl). 2017;130(2):130-134.
49. Buckstein R, Wells RA, Zhu N, et al. Patient- related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174(1):88-101.
50. Deschler B, Ihorst G, Schnitzler S, Bertz H,
1492
haematologica | 2020; 105(6)